March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Progesterone Treatment In Rodent Anterior Ischemic Optic Neuropathy
Author Affiliations & Notes
  • Rachael S. Allen
    Emergency Medicine,
    Ophthalmology,
    Emory University, Atlanta, Georgia
  • Timothy W. Olsen
    Ophthalmology,
    Emory University, Atlanta, Georgia
  • Heather A. Cale
    Emergency Medicine,
    Emory University, Atlanta, Georgia
  • Katherine C. Morrison
    Emergency Medicine,
    Emory University, Atlanta, Georgia
  • Jeffrey H. Boatright
    Ophthalmology,
    Emory University, Atlanta, Georgia
  • Machelle T. Pardue
    Ophthalmology,
    Emory University, Atlanta, Georgia
    Rehab R & D Center of Excellence, Atlanta VA Medical Center, Decatur, Georgia
  • Donald G. Stein
    Emergency Medicine,
    Emory University, Atlanta, Georgia
  • Footnotes
    Commercial Relationships  Rachael S. Allen, None; Timothy W. Olsen, None; Heather A. Cale, None; Katherine C. Morrison, None; Jeffrey H. Boatright, None; Machelle T. Pardue, None; Donald G. Stein, None
  • Footnotes
    Support  H. Allen & Co., The Abraham J. & Phyllis Katz Foundation, Foundation Fighting Blindness, Research to Prevent Blindness, NIH NEI R01EY014026, R01EY016470, R24EY017045, P30EY006360, and T32EY007092-25
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3475. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rachael S. Allen, Timothy W. Olsen, Heather A. Cale, Katherine C. Morrison, Jeffrey H. Boatright, Machelle T. Pardue, Donald G. Stein; Progesterone Treatment In Rodent Anterior Ischemic Optic Neuropathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3475.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Optic nerve stroke, or anterior ischemic optic neuropathy (AION), is the leading cause of sudden vision loss related to optic nerve dysfunction in older adults. No effective treatment currently exists. The neurosteroid progesterone has protective effects in animal models of traumatic brain injury, stroke, and spinal cord injury, including reduced inflammation, swelling, and neuronal death; and improved behavioral and functional recovery. The substantial overlap of mechanisms involved in optic nerve stroke and mechanisms modulated by progesterone leads us to hypothesize that progesterone protects against retinal ganglion cell death in optic nerve stroke.

Methods: : The rodent AION model was used to induce monocular optic nerve stroke, while the contralateral eye served as a control. Rats were treated systemically with vehicle or progesterone at 1, 6, 24, 48, 72, 96, and 120 hours post surgery. Electroretinograms and visual evoked potentials (VEPs) were performed at 3 days post surgery. At 14 days, rats were euthanized, eyes were enucleated, and retinal flat mounts were immuno-labeled with the retinal ganglion cell specific antibody, Brn3a. Retinal ganglion cells were counted using an imaging analysis software.

Results: : As measured by VEPs, stroke eyes from vehicle treated animals (n = 8) performed at 68% of the level of their contralateral control eyes. Meanwhile, stroke eyes from progesterone treated animals (n = 7) performed at 95% of the level of their contralateral controls (p = 0.08). These results indicate clinically relevant improvement in visual function. Additionally, stroke retinas from progesterone treated animals (n = 8) had more Brn3a stained retinal ganglion cells than their vehicle treated counterparts (n = 8) (approximately 10,000 more or 15% on average).

Conclusions: : Given the current observations along with the growing literature on the neuroprotective effects of progesterone in cerebral stroke and TBI, progesterone may prove to be an effective treatment in the rodent anterior ischemic optic neuropathy model as well.

Keywords: neuroprotection • neuro-ophthalmology: optic nerve • ischemia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×